Status:
COMPLETED
Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal ...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Current treatment with insulin NPH or glargine
- The selection of the subjects will be at the discretion of the individual physician
Exclusion
- Current treatment with insulin detemir
- Previous enrolment in this study
- Hypersensitivity to insulin detemir or to any of the excipients.
- Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
206 Patients enrolled
Trial Details
Trial ID
NCT00697450
Start Date
July 1 2008
End Date
December 1 2009
Last Update
November 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Prague, Czechia, 16000